907587-49-9

Upstream product

• 907587-46-6 methyl 4-[(2-nitro-5-(trifluoromethyl)phenoxy)methyl]benzoate 
• 402-17-5 2-nitro-5-trifluoromethylphenol 
• 402-54-0 p-nitrobenzotrifluoride 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 909897-03-6 methyl 4-{[2-[(thien-3-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 909896-99-7 methyl 4-{[2-[(pyridin-2-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 909896-93-1 methyl 4-{[2-[(pyridin-3-ylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 209685-47-2 methyl 4-({2-[(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy}methyl)benzoate 
• 209686-79-3 methyl 4-{[2-[(cyclopentylmethyl)(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 907587-59-1 methyl 4-{[2-[neopentyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 907587-57-9 methyl 4-{[2-[(phenylsulfonyl)(propyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 907587-56-8 methyl 4-{[2-[ethyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 209685-50-7 methyl 4-{[2-[isopropyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoate 
• 913078-91-8 methyl 3-(4-{[2-{isobutyl[(5-methyl-2-furyl)sulfonyl]amino}-5-(trifluoromethyl)phenoxy]methyl}phenyl)prop-2-ynoate 
• 909897-29-6 methyl 4-{[2-{[(3,5-dimethylisoxazol-4-yl)sulfonyl](isobutyl)amino}-5-(trifluoromethyl)phenoxy]methyl}benzoate 

Relevant academic research and scientific papers

Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists

4-({2-[Isobutyl(phenylsulfonyl)amino]-5-(trifluoromethyl)phenoxy}methyl)benzoic acid (1) is a functional PGE2 antagonist selective for EP1 receptor subtype. Analogs of 1, in which the phenyl-sulfonyl moiety has been replaced with more hydrophil

Discovery of new chemical leads for selective EP1 receptor antagonists

A series of 4-({2-[alkyl(phenylsulfonyl)amino]phenoxy}methyl)benzoic acids were identified as functional PGE2 antagonists with selectivity for the EP1 receptor subtype starting from a chemical lead 1, which was found while screening our in-house compound library. Discovery of the optimized analogs 21-23 is presented here and structure-activity relationships (SAR) are also discussed.

Further optimization of sulfonamide analogs as EP1 receptor antagonists: Synthesis and evaluation of bioisosteres for the carboxylic acid group

4-{[2-[(2-Furylsulfonyl)(isobutyl)amino]-5-(trifluoromethyl)phenoxy]methyl}benzoic acid analogs 2a and b and a series of the acid analogs, in which the carboxylic acid residue of 2b was replaced with various kinds of carboxylic acid bioisosteres, were synthesized and evaluated as EP1 receptor antagonists. Compound 2b and its monocyclic acid analogs, in which the carboxylic acid residue of 2b was replaced with monocyclic acid bioisosteres, were found to show potent EP1 receptor antagonist activity. Optimization of the linker Y between the phenyl moiety and the carboxylic acid residue of 2b was also carried out (Table 5). Compounds 2b and 16 and 17 possessing conformationally restricted linker Y were found to show the most optimized potency among the tested compounds. Cytochrome P450 inhibition of optimized compounds was also investigated. Details of the structure-activity relationship study are presented.

Sulfonamide and carboxamide derivatives and drugs containing the same as the active ingredient

The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient: (wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1is —COR1, —CH═CH—COR1/